Jiefei Han

发表

Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases.

X. Xie, Jie He, Cheng-Li Song, 2018, Cancer research.

Polymorphism of Rs9387478 Correlates with Overall Survival in Female Nonsmoking Patients with Lung Cancer

N. Rothman, Yi-long Wu, Jin-Ji Yang, 2016, The International journal of biological markers.

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer

Jie He, Bingding Huang, Shuhang Wang, 2019, Journal of Immunotherapy for Cancer.

Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2015, Lung cancer.

Soluble c‐Met Levels Correlated With Tissue c‐Met Protein Expression in Patients With Advanced Non–Small‐Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017, Clinical lung cancer.

The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma.

Yi-long Wu, Xuchao Zhang, Jian Su, 2015, Journal of thoracic disease.

Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer

X. Wang, Shuhang Wang, Y. Shao, 2020, EBioMedicine.

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers

D. Carbone, Wei Zhao, G. Feng, 2021, Science Advances.

Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors.

Shuhang Wang, Junling Li, Yanhua Tian, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Jing Zhao, Guoqiang Wang, Jun Zhao, 2019, JAMA oncology.

TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Shuhang Wang, Yanhua Tian, H. Bai, 2019, Cancer Immunology Research.

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

X. Wang, Shuhang Wang, Junling Li, 2020 .

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Clinical lung cancer.

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib

H. Bai, Jie Wang, Jiefei Han, 2021, Translational oncology.

Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment.

Ying Cheng, Yi-long Wu, Yuankai Shi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Case report: The treatment for olfactory neuroblastoma combined with leptomeningeal carcinomatosis via an ommaya reservoir

F. Chen, xun kang, Jiefei Han, 2023, Frontiers in Oncology.

Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling

Zhaoli Chen, Jie He, J. Gu, 2018, Clinical Cancer Research.

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

Jie Tian, Yanhua Tian, Yang Du, 2020, Journal for ImmunoTherapy of Cancer.

Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, Journal of thoracic disease.